Erste Asset Management GmbH Acquires New Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Erste Asset Management GmbH bought a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 27,000 shares of the company's stock, valued at approximately $1,315,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA boosted its holdings in Kymera Therapeutics by 11.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company's stock valued at $21,458,000 after purchasing an additional 47,507 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Kymera Therapeutics by 19.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company's stock worth $4,663,000 after acquiring an additional 25,317 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Kymera Therapeutics in the 2nd quarter worth approximately $4,271,000. Eventide Asset Management LLC lifted its holdings in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company's stock worth $24,039,000 after acquiring an additional 45,803 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 391.2% in the 2nd quarter. E Fund Management Co. Ltd. now owns 48,946 shares of the company's stock worth $1,461,000 after acquiring an additional 38,981 shares during the last quarter.

Kymera Therapeutics Trading Down 1.9 %

Shares of NASDAQ KYMR traded down $0.89 during mid-day trading on Wednesday, reaching $46.02. The company had a trading volume of 373,524 shares, compared to its average volume of 583,955. The firm has a 50 day simple moving average of $46.55 and a two-hundred day simple moving average of $42.45. The stock has a market cap of $2.98 billion, a P/E ratio of -19.67 and a beta of 2.16. Kymera Therapeutics, Inc. has a 52-week low of $20.46 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company's revenue was down 20.9% on a year-over-year basis. During the same period last year, the firm posted ($0.90) EPS. On average, equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In other news, Director Pamela Esposito sold 13,500 shares of the firm's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 15.82% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on KYMR shares. Guggenheim upped their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Leerink Partnrs upgraded shares of Kymera Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. Wolfe Research raised shares of Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 target price on the stock in a research note on Monday, August 26th. Wells Fargo & Company raised shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $38.00 to $57.00 in a research note on Monday. Finally, Truist Financial reaffirmed a "buy" rating and set a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $53.40.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.